Management of Neonatal herpes simplex virus infections
Symposium on Protocols for Managing Severe Infections-II
As many as 2,500 infants develop neonatal herpes each year, most of whom are born to women with no history or physical findings suggestive of genital herpes. Infection usually takes one of three forms: 1) disease localized to skin, eyes, and mucous membranes, 2) localized central nervous system infection, or 3) disseminated infection. Exposure to the virus occurs during passage through an infected birth canal, but 5% of infants acquire the infectionin utero. The mortality rate is 31% for disseminated infection and 6% for localized central nervous system disease; long-term neurologic sequelae are seen in 17% and 70% of survivors, respectively. Diagnosis is made by isolating of the virus from skin lesions or other involved sites. The polymerase chain reaction for the detection of viral DNA in cerebrospinal fluid or serum is now the diagnostic test of choice for central nervous system or disseminated neonatal herpes because it has higher sensitivity than traditional culture methods. Treatment is with high-dose intravenous acyclovir (60 mg/kg per day in three divided doses), with adjustments made for infants with renal or hepatic insufficiency. Supportive measures and neuroimaging studies are often required. Acyclovir is administered for three weeks, but infants with disease localized to the skin, eyes, and mucous membranes can be treated for two weeks if the cerebrospinal fluid polymerase chain reaction assay is negative for herpes simplex virus DNA. Prevention of infection in infants can be accomplished by cesarean delivery when women have active lesions at the onset of labor. Neonates delivered through an infected birth canal should be screened between 24 and 48 hours of age with viral cultures of eyes, nasopharynx, mouth, and rectum. If positive, they should be treated with acyclovir even if asymptomatic. Suppressive acyclovir therapy beginning at 36 weeks gestation is often prescribed for women with frequent recurrences of genital herpes.
Key wordsHerpes simplex virus Pregnancy complications infectious Herpes encephalitis Acyclovir Cesarean section
Armstrong GL, Schillinger J, Markowitz Let al.
Incidence of herpes simplex virus type 2 infection in the United States.Am J Epidemiol
2001; 153: 912–920.PubMedCrossRefGoogle Scholar
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002.MMWR
2002; 51(RR-6): 1–78.Google Scholar
Brown ZA, Selke S, Zeh Jet al.
The acquisition of herpes simplex virus during pregnancy.N Engl J Med
1997; 337: 509–515.PubMedCrossRefGoogle Scholar
Fleming DT, McQuillan GM, Johnson REet al.
Herpes simplex virus type 2 in the United States, 1976 to 1994.N Engl J Med
1997; 337: 1105–1111.PubMedCrossRefGoogle Scholar
Kaur R, Gupta N, Nair D, Kakkar M, Mathur MD. Screening for TORCH infections in pregnant women: a report from Delhi.Southeast Asian J Trop Med Public Health
1999; 30: 284–286.PubMedGoogle Scholar
Cowan FM, French RS, Mayaud Pet al.
Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka.Sex Transm Infect
2003; 79: 286–290.PubMedCrossRefGoogle Scholar
Jonsson MK, Wahren B. Sexually transmitted herpes simplex viruses.Scand f Infect Dis
2004; 36: 93–101.CrossRefGoogle Scholar
Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding.J Antimicrob Chemother
2000; 45: 1–8.PubMedCrossRefGoogle Scholar
Kimberlin DW, Rouse DJ. Genital herpes.N Engl J Med
2004; 350: 1970–1977.PubMedCrossRefGoogle Scholar
Wald A, Zeh J, Selke Set al.
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.N Engl J Med
2000; 342: 844–850.PubMedCrossRefGoogle Scholar
Kimberlin DW, Lin C-Y, Jacobs RFet al.
Natural history of neonatal herpes simplex virus infections in the acyclovir era.Pediatrics
2001; 108: 223–229.PubMedCrossRefGoogle Scholar
Freij BJ, Sever JL. Fetal herpes simplex virus infection. In Buyse ML, ed.Birth Defects Encyclopedia
. Boston; Blackwell Scientific Publications, 1990; 713–714.Google Scholar
Kimberlin DW. Neonatal herpes simplex infection.Clin Microbiol Rev
2004; 17: 1–13.PubMedCrossRefGoogle Scholar
Filippine MM, Katz BZ. Neonatal herpes simplex virus infection presenting with fever alone.J Hum Virol
2001; 4: 223–225.PubMedGoogle Scholar
Toth C, Harder S, Yager J. Neonatal herpes encephalitis: a case series and review of clinical presentation.Can J Neurol Sci
2003; 30: 36–40.PubMedGoogle Scholar
Kimura H, Futamura M, Ito Yet al.
Relapse of neonatal herpes simplex virus infection.Arch Dis Child Fetal Neonatal Ed
2003; 88: F483-F486.PubMedCrossRefGoogle Scholar
Whitley R, Arvin A, Prober Cet al.
Predictors of morbidity and mortality in neonates with herpes simplex virus infections.N Engl J Med
1991; 324: 450–454.PubMedCrossRefGoogle Scholar
Jerome KR, Ashley RL. Herpes simplex viruses and herpes B virus. In Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds.Manual of Clinical Microbiology
ed. Washington, DC; ASM Press, 2003; 1291–1303.Google Scholar
Kimura H, Ito Y, Futamura Met al.
Quantitation of viral load in neonatal herpes simplex virus infection and comparison between type 1 and type 2.J Med Virol
2002; 67: 349–353.PubMedCrossRefGoogle Scholar
Whitley R, Arvin A, Prober Cet al.
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection.N Engl J Med
1991; 324: 444–449.PubMedCrossRefGoogle Scholar
Kimberlin DW, Lin C-Y, Jacobs RFet al.
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections.Pediatrics
2001; 108: 230–238.PubMedCrossRefGoogle Scholar
Pramod NP, Thyagarajan SP, Mohan KVK, Anandakannan K. Acyclovir resistance in herpes simplex virus isolates from keratitis cases: an analysis from a developing country.Microbiol Immunol
2000; 44: 241–247.PubMedGoogle Scholar
Nyquist A-C, Rotbart HA, Cotton Met al.
Acyclovir-resistant neonatal herpes simplex virus infection of the larynx.J Pediatr
1994; 124: 967–971.PubMedCrossRefGoogle Scholar
Kesson AM. Management of neonatal herpes simplex virus infection.Pediatr Drugs
2001; 3: 81–90.CrossRefGoogle Scholar
Reynolds SJ, Risbud AR, Shepherd MEet al.
Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India.J Inject Dis
2003; 187: 1513–1521.CrossRefGoogle Scholar
Leonard JR, Moran CJ, Cross DT III, Wippold FJ II, Schlesinger Y, Storch GA. MR imaging of herpes simplex type 1 encephalitis in infants and young children: a separate pattern of findings.AJR Am J Roentgenol
2000; 174: 1651–1655.PubMedGoogle Scholar
Kimberlin D, Powell D, Gruber Wet al.
Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial.Pediatr Infect Dis J
1996; 15: 247–254.Google Scholar
American College of Obstetricians and Gynecologists. ACOG practice bulletin. Management of herpes in pregnancy. Number 8 October 1999. Clinical management guidelines for obstetrician-gynecologists.Int J Gynaecol Obstet
2000; 68: 165–173.CrossRefGoogle Scholar
Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant.JAMA
2003; 289: 203–209.PubMedCrossRefGoogle Scholar
Garland SM, Lee TN, Sacks S. Do antepartum herpes simplex virus cultures predict intrapartum shedding for pregnant women with recurrent disease?Infect Dis Obstet Gynecol
1999; 7: 230–236.PubMedCrossRefGoogle Scholar
Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD Jr. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review.Obstet Gynecol
2003; 102: 1396–1403.PubMedCrossRefGoogle Scholar
Centers for Disease Control and Prevention. Pregnancy outcomes following systemic prenatal acyclovir exposure — June 1, 1984-June 30, 1993.MMWR
1993; 42: 806–809.Google Scholar
© Dr. K C Chaudhuri Foundation 2004